Humira gains indication
The FDA has approved Humira (adalimumab, from Abbott) for the treatment of juvenile rheumatoid arthritis (JRA).This approval was based on a 48-week study involving 171 children aged 4 to 17 years. The results showed significantly fewer disease flares while receiving Humira compared to placebo.
Humira, a tumor necrosis factor-alpha blocker, is already indicated for the treatment of Crohn's disease, adult rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis, and ankylosing spondylitis.
For more information call (800) 633-9110 or visit www.humira.com.